Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.63 |
| ▸ | NPY4R | P50391 | 10/20 | 0.56 |
| ▸ | NPY1R | P25929 | 8/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.56 |
| ▸ | NPY2R | P49146 | 6/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 6/20 | 0.56 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15471603 | 0.94 | TFPI (0.66) | TFPIVIPR1 | |
| SCHEMBL13540720 | 0.94 | TFPI (0.60) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13540749 | 0.92 | TFPI (0.63) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL15471605 | 0.92 | TFPI (0.69) | TFPIVIPR1 | |
| SCHEMBL13540730 | 0.91 | TFPI (0.60) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13540742 | 0.90 | TFPI (0.65) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13540733 | 0.90 | TFPI (0.65) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL15471608 | 0.90 | TFPI (0.65) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13540731 | 0.90 | TFPI (0.60) | TFPINPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13540717 | 0.90 | TFPI (0.60) | TFPINPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181301-B2 | TDF-related compounds and analogs thereof | THRASOS INNOVATION, INC. (CA) | 2015-11-10 | — | — | US | disclosed |
| US-20150132355-A1 | TDF-RELATED COMPOUNDS AND ANALOGS THEREOF | THRASOS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-8916686-B2 | TDF-related compounds and analogs thereof | THRASOS INNOVATION, INC. (CA) | 2014-12-23 | — | — | US | disclosed |
| US-20140044754-A1 | TDF-RELATED COMPOUNDS AND ANALOGS THEREOF | THRASOS, INC. | 2014-02-13 | — | — | US | disclosed |
| US-8410246-B2 | TDF-related compounds and analogs thereof | THRASOS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100015150-A1 | Tdf-related compounds and analogs thereof | THRASOS THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015150-A1 | Tdf-related compounds and analogs thereof | PGF, EDF1, DCTD | TFPI 149/4885NPY4R 1912/4885NPY1R 1862/4885 |
| US-20150132355-A1 | TDF-RELATED COMPOUNDS AND ANALOGS THEREOF | PGF, EDF1, DCTD | TFPI 149/4885NPY4R 1912/4885NPY1R 1862/4885 |
| US-20140044754-A1 | TDF-RELATED COMPOUNDS AND ANALOGS THEREOF | PGF, EDF1, DCTD | TFPI 149/4885NPY4R 1912/4885NPY1R 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.